Sprint Bioscience Beheer

Beheer criteriumcontroles 3/4

Sprint Bioscience's CEO is Johan Emilsson, appointed in Oct 2023, has a tenure of 1.08 years. total yearly compensation is SEK1.68M, comprised of 25% salary and 75% bonuses, including company stock and options. directly owns 0.029% of the company’s shares, worth SEK38.25K. The average tenure of the management team and the board of directors is 3.3 years and 4.8 years respectively.

Belangrijke informatie

Johan Emilsson

Algemeen directeur

SEK 1.7m

Totale compensatie

Percentage CEO-salaris	25.0%
Dienstverband CEO	1.1yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Estimating The Fair Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Jun 12

A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Feb 19

Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

Nov 19

Analyse CEO-vergoeding

Hoe is Johan Emilsson's beloning veranderd ten opzichte van Sprint Bioscience's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-SEK 19m
Jun 30 2024	n/a	n/a	SEK 15m
Mar 31 2024	n/a	n/a	SEK 9m
Dec 31 2023	SEK 2m	SEK 420k	-SEK 438k

Compensatie versus markt: Johan's total compensation ($USD157.59K) is below average for companies of similar size in the Swedish market ($USD242.77K).

Compensatie versus inkomsten: Insufficient data to compare Johan's compensation with company performance.

CEO

Johan Emilsson (40 yo)

1.1yrs

Tenure

SEK 1,680,000

Compensatie

Mr. Johan Emilsson is Chief Executive Officer of Sprint Bioscience AB (publ) since October 01, 2023. He has broad experience in business development within the pharmaceutical industry and most recently fro...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Johan Emilsson	Chief Executive Officer	1.1yrs	SEK 1.68m	0.029% SEK 38.2k
Pär Nordlund	Founder	no data	SEK 25.00k	0.91% SEK 1.2m
Martin Andersson	Co-Founder & Chief Scientific Officer	15.8yrs	geen gegevens	0.39% SEK 523.4k
Kenth Hallberg	Founder & Director of Structural Chemistry	no data	geen gegevens	geen gegevens
Mathias Skalmstad	Chief Financial Officer	3.3yrs	geen gegevens	0.10% SEK 137.7k
Anne-Marie Wenthzel	Chief Business Officer	no data	geen gegevens	0.26% SEK 350.0k

3.3yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: SPRINT's management team is considered experienced (3.3 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Svein Mathisen	Independent Director	4.8yrs	SEK 150.00k	0.064% SEK 86.0k
Bjorn Sjostrand	Independent Chairman of the Board	3.8yrs	SEK 300.00k	1.26% SEK 1.7m
Lewis Cantley	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Rune Nordlander	Director	14.8yrs	SEK 150.00k	15.13% SEK 20.2m
Fredrik Lehmann	Independent Director	5.5yrs	SEK 150.00k	0.072% SEK 95.6k
Robert Devita	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gunilla Enblad	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Karen From	Independent Director	1.5yrs	SEK 88.00k	geen gegevens

4.8yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: SPRINT's board of directors are considered experienced (4.8 years average tenure).

Sprint Bioscience Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

High number of new and inexperienced directors

Director recently bought kr336k worth of stock

Sprint Bioscience AB (publ) Appoints Erik Kinnman as New CEO in Place of Charlotte Leife

Recent updates

Third quarter 2024 earnings released: kr0.075 loss per share (vs kr0.41 profit in 3Q 2023)

Investor sentiment improves as stock rises 24%

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 17%

Full year 2023 earnings released: kr0.006 loss per share (vs kr1.43 loss in FY 2022)

Third quarter 2023 earnings released: EPS: kr0.41 (vs kr0.33 loss in 3Q 2022)

Second quarter 2023 earnings released: kr0.17 loss per share (vs kr0.45 loss in 2Q 2022)

Estimating The Fair Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Now 23% undervalued after recent price drop

Now 21% undervalued after recent price drop

A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Full year 2022 earnings released: kr1.43 loss per share (vs kr0.85 loss in FY 2021)

Price target decreased to kr3.30

Third quarter 2022 earnings released: kr0.33 loss per share (vs kr0.54 profit in 3Q 2021)

Second quarter 2022 earnings released: kr0.45 loss per share (vs kr0.60 loss in 2Q 2021)

First quarter 2022 earnings: EPS misses analyst expectations

Sprint Bioscience Launches NIMA at BIO International

Forecast to breakeven in 2023

High number of new and inexperienced directors

Full year 2021 earnings: EPS misses analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations

Third quarter 2021 earnings released: EPS kr0.54 (vs kr0.36 loss in 3Q 2020)

Director recently bought kr336k worth of stock

Sprint Bioscience AB (publ) Adds New Cancer Drug Program to its Project Portfolio

Second quarter 2021 earnings released: kr0.60 loss per share (vs kr1.01 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.65 loss per share (vs kr0.79 loss in 1Q 2020)

Sprint Bioscience AB (publ) announced that it has received SEK 20.713701 million in funding

Interim Chief Executive Officer Charlotte Leife has left the company

Sprint Bioscience AB (publ) Appoints Erik Kinnman as New CEO in Place of Charlotte Leife

Revenue and earnings beat expectations

New 90-day low: kr6.52

Full year 2020 earnings released: kr2.02 loss per share (vs kr1.92 loss in FY 2019)

New 90-day low: kr7.10

Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

Third quarter 2020 earnings released: kr0.36 loss per share

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd